ChristopherLBowlusMD

Gastroenterology • Sacramento, CA

Inflammatory Bowel Disease

Lena Valente Professor and Chief Division of Gastroenterology and Hepatology UC Davis School of Medicine

Join to view full profile

Dr. Bowlus is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Bowlus' full profile

Already have an account?

Office
4150 V St
Ste 3500
Sacramento, CA 95817
Phone+1 916-734-3751

Fax+1 916-734-7908
Is this information wrong?

Education & Training

Yale-New Haven Medical CenterFellowship, Gastroenterology, 1993 - 1996
University of California Davis HealthResidency, Internal Medicine, 1990 - 1993
Saint Louis University School of MedicineClass of 1990

Certifications & Licensure

CA State Medical License 1991 - 2025
CT State Medical License 1993 - 1999
American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

Fellow (FAASLD) American Association for the Study of Liver Disease
Fellow (AGAF) American Gastroenterological Association, 2011
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012

Clinical Trials

Initial Study of Rituximab to Treat Primary Biliary Cirrhosis Start of enrollment: 2007 Jan 01
Completed
Phase 1, Phase 2
Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease Start of enrollment: 2007 Oct 01
Terminated
Phase 2
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis Start of enrollment: 2012 Jan 01
Completed
Phase 3
Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC) Start of enrollment: 2013 Mar 04
Completed
Phase 2
Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis Start of enrollment: 2013 Dec 03
Completed
Phase 2
Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis Start of enrollment: 2013 Aug 01
Completed
Phase 2
Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis Start of enrollment: 2014 Mar 01
Completed
Phase 2
Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis Start of enrollment: 2014 Sep 01
Completed
Phase 4
Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC) Start of enrollment: 2015 Feb 09
Completed
Phase 2
Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Start of enrollment: 2014 Dec 26
Terminated
Phase 4
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis Start of enrollment: 2015 May 01
Withdrawn
Phase 2
Identification of Inflammatory and Fibrotic Biomarkers in PBC and NAFLD Patients Start of enrollment: 2015 May 01
Completed
Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies Start of enrollment: 2016 Apr 30
Completed
Phase 2
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) Start of enrollment: 2015 Nov 01
Terminated
Phase 2
PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis Start of enrollment: 2016 Mar 14
Completed
Phase 2
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis Start of enrollment: 2016 Oct 01
Active, not recruiting
Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis Start of enrollment: 2016 Dec 01
Terminated
Phase 2
Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis Start of enrollment: 2016 Nov 29
Completed
Phase 2
Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC) Start of enrollment: 2016 Nov 28
Completed
Phase 2
Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol. Start of enrollment: 2017 Jun 26
Completed
Phase 2
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) Start of enrollment: 2017 Dec 12
Recruiting
Phase 3
Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis Start of enrollment: 2018 Jul 01
Recruiting
Phase 2
CM-101 in PSC Patients -The SPRING Study Start of enrollment: 2020 Oct 01
Active, not recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Hypercholesterolemia Is Associated With Dysregulation of Lipid Metabolism and Poor Prognosis in Primary Biliary Cholangitis.
Linhua Zheng, Siyuan Tian, Chunmei Yang, Bo Li, Gui Jia, Yansheng Liu, Ruiqing Sun, Xiufang Wang, Juan Deng, Miao Zhang, Lina Cui, Changcun Guo, Xinmin Zhou, Patrick S...> ;Clinical Gastroenterology and Hepatology. 2024 Feb 13
Per-oral cholangioscopy in patients with primary sclerosing cholangitis: a 12-month follow-up study.
Mohamed, R., Aabakken, L., Ponsioen, C., Adler, D., Forbes, N., Paulsen, V., Voermans, R., Peetermans, J., Rousseau, M., Eksteen, B., Tejaswi, S., Bowlus, C., Urayama, S.> ;Endoscopy International Open. 2024 Feb 1
African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitis.
Maryam Yazdanfar, Joseph Zepeda, Richard Dean, Jialin Wu, Cynthia Levy, David Goldberg, Craig Lammert, Stacey Prenner, K Rajender Reddy, Daniel Pratt, Lisa Forman, Dav...> ;Hepatology Communications. 2024 Feb 1
Autoimmune Markers in Primary Biliary Cholangitis.
Christopher L Bowlus, Shivani K Shah> ;Clinics in Liver Disease. 2024 Feb 1
Editorial: The evolving paradigms and treatments for primary biliary cholangitis-Authors' reply.
Mayo, M., Vierling, J., Bowlus, C.> ;Alimentary Pharmacology & Therapeutics. 2024 Jan 1
Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis.
Kremer, A., Mayo, M., Hirschfield, G., Levy, C., Jones, D., Johnson, J., McWherter, C., Choi, Y., Bowlus, C.> ;Hepatology. 2023 Dec 20
2 citations
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.
Marlyn J Mayo, John M Vierling, Christopher L Bowlus, Cynthia Levy, Gideon M Hirschfield, Guy W Neff, Michael R Galambos, Stuart C Gordon, Brian B Borg, Stephen A Harr...> ;Alimentary Pharmacology & Therapeutics. 2024 Jan 1
Interobserver agreement and prognostic value of image-based scoring systems in patients with primary sclerosing cholangitis.
Erick Cruz Grave, Thomas Loehfelm, Michael T Corwin, Joseph Zepeda, Harjot K Bath, Sandeep Dhaliwal, Maryam Yazdanfar, Christopher L Bowlus> ;Abdominal Radiology. 2024 Jan 1
2 citations
The gut ecosystem and immune tolerance.
Tihong Shao, Ronald Hsu, Desiree L Rafizadeh, Li Wang, Christopher L Bowlus, Narendra Kumar, Jayshree Mishra, Suraj Timilsina, William M Ridgway, M Eric Gershwin, Afta...> ;Journal of Autoimmunity. 2023 Dec 1
Correction to: Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis.
Marlyn J Mayo, Elizabeth Carey, Helen T Smith, Andrea R Mospan, Megan McLaughlin, April Thompson, Heather L Morris, Robert Sandefur, W Ray Kim, Christopher Bowlus, , C...> ;Digestive Diseases and Sciences. 2023 Oct 1
2 citations
Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study.
Christopher L Bowlus, Bertus Eksteen, Angela C Cheung, Douglas Thorburn, Cynthia A Moylan, Paul J Pockros, Lisa M Forman, Alejandro Dorenbaum, Gideon M Hirschfield, Ci...> ;Hepatology Communications. 2023 Jun 1
3 citations
Recent Advances in the Management of Primary Sclerosing Cholangitis.
David N Assis, Christopher L Bowlus> ;Clinical Gastroenterology and Hepatology. 2023 Jul 1
5 citations
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Gideon M Hirschfield, Mitchell L Shiffman, Aliya Gulamhusein, Kris V Kowdley, John M Vierling, Cynthia Levy, Andreas E Kremer, Ehud Zigmond, Pietro Andreone, Stuart C ...> ;Hepatology. 2023 Aug 1
4 citations
PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic pa...
Michael Trauner, Chuhan Chung, Kate Sterling, Xiangyu Liu, Xiaomin Lu, Jun Xu, Clare Tempany-Afdhal, Zachary D Goodman, Martti Färkkilä, Atsushi Tanaka, Palak Trivedi,...> ;BMC Gastroenterology. 2023 Mar 15
6 citations
Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis.
Marlyn J Mayo, Elizabeth Carey, Helen T Smith, Andrea R Mospan, Megan McLaughlin, April Thompson, Heather L Morris, Robert Sandefur, W Ray Kim, Christopher Bowlus, , C...> ;Digestive Diseases and Sciences. 2023 Mar 1
4 citations
Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis.
Kris V Kowdley, Christopher L Bowlus, Cynthia Levy, Marlyn J Mayo, Daniel S Pratt, Raj Vuppalanchi, Zobair M Younossi> ;The American Journal of Gastroenterology. 2023 Feb 1
Reply: Insurance should cover vancomycin for primary sclerosing cholangitis.
Christopher L Bowlus, Lionel Arrivé, Annika Bergquist, Mark Deneau, Lisa Forman, Sumera I Ilyas, Keri E Lunsford, Mercedes Martinez, Gonzalo Sapisochin, Rachna Shroff,...> ;Hepatology. 2023 Jun 1
Reply: Living donor liver transplantation for people with PSC.
Lisa M Forman, Gonzalo Sapisochin, David N Assis, Lionel Arrivé, Annika Bergquist, Christopher L Bowlus, Mark Deneau, Sumera I Ilyas, Keri E Lunsford, Mercedes Martine...> ;Hepatology. 2023 May 1
Automated electronic health registry-based hepatitis B screening.
Eric W Chak, Randy Luna, Scott MacDonald, Susan L Stewart, Moon S Chen Jr, Christopher Bowlus> ;Journal of Viral Hepatitis. 2023 Mar 1
16 citations
GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus.
Cynthia Levy, Stuart Kendrick, Christopher L Bowlus, Atsushi Tanaka, David Jones, Andreas E Kremer, Marlyn J Mayo, Nazneen Haque, Robyn von Maltzahn, Matthew Allinder,...> ;Clinical Gastroenterology and Hepatology. 2023 Jul 1
1 citations
Treatment of Primary Biliary Cholangitis: First-Line and Second-Line Therapies.
Chung-Heng Liu, Christopher L Bowlus> ;Clinics in Liver Disease. 2022 Nov 1
20 citations
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Con...
C Fiorella Murillo Perez, Holly Fisher, Shaun Hiu, Dorcas Kareithi, Femi Adekunle, Tracy Mayne, Elizabeth Malecha, Erik Ness, Adriaan J van der Meer, Willem J Lammers,...> ;Gastroenterology. 2022 Dec 1
57 citations
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma.
Christopher L Bowlus, Lionel Arrivé, Annika Bergquist, Mark Deneau, Lisa Forman, Sumera I Ilyas, Keri E Lunsford, Mercedes Martinez, Gonzalo Sapisochin, Rachna Shroff,...> ;Hepatology. 2023 Feb 1
1 citations
Reply to: "Seladelpar in patients with primary biliary cholangitis: Need for a closer look!"
Christopher L Bowlus, Cynthia Levy, Gideon M Hirschfield> ;Journal of Hepatology. 2022 Nov 1
12 citations
Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.
Michael Trauner, Christopher L Bowlus, Aliya Gulamhusein, Bilal Hameed, Stephen H Caldwell, Mitchell L Shiffman, Charles Landis, Andrew J Muir, Andrew Billin, Jun Xu, ...> ;Clinical Gastroenterology and Hepatology. 2023 Jun 1
Join now to see all

Lectures

2013 UC Davis Update in Gastroenterology and Hepatology
UC Davis Health System, Monterey, California - 8/24/2013
31st Annual UC Davis Infectious Diseases Conference,2013
UC Davis Health System, Sacramento, California - 2/1/2013
2012 Update in Gastroenterology & Hepatology for the Primary Care Practitioner
UC Davis Health System, Olympic Valley, California - 8/18/2012

Press Mentions

Meet Antonio Mendoza-Ladd, UC Davis Health’s New Medical Director of EndoscopyFebruary 23rd, 2023
CymaBay Reports Third Quarter and Nine Months Ended September 30, 2022 Financial Results and Provides Corporate UpdateNovember 14th, 2022
Mirum Pharmaceuticals Announces First Patient Enrolled in Phase 2b VISTAS Clinical Study Evaluating Volixibat in Adult Patients with Primary Sclerosing CholangitisJanuary 14th, 2021
Join now to see all

Grant Support

Oxidative Mutagenesis:Iron, Ascorbic Acid And GenesNational Institute Of Environmental Health Sciences2001–2002
Cloning Of The Hemochromatosis LocusNational Institute Of Diabetes And Digestive And Kidney Diseases1997–2000
Cloning Of The Hemochromatosis LocusNational Institute Of Diabetes And Digestive And Kidney Diseases1996–1997